Skip to main content

REVIEW article

Front. Surg.
Sec. Colorectal and Proctological Surgery
Volume 11 - 2024 | doi: 10.3389/fsurg.2024.1498529
This article is part of the Research Topic Novel Techniques for Colorectal Cancer View all articles

Challenges following CRS and HIPEC Surgery in Cancer Patients with Peritoneal Metastasis: A Comprehensive Review of Clinical Outcomes

Provisionally accepted
Mehdi Karimi Mehdi Karimi 1*Niyousha Shirsalimi Niyousha Shirsalimi 2Eshagh Sedighi Eshagh Sedighi 3
  • 1 Bogomolets National Medical University (NMU), Kyiv, Ukraine
  • 2 Faculty of Medicine, Hamadan University of Medical Science (UMSHA), Hamadan, Hamadan, Iran
  • 3 Department of Veterinary Medicine, Islamic Azad University Branch of Urmia, Urmia, Iran

The final, formatted version of the article will be published soon.

    Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) are a pair of relatively modern therapeutic surgical methods in advanced cancerous patients with peritoneal metastasis (PM). The goal of CRS+HIPEC is treatment or to improve survival outcomes, which are linked to high morbidity side effects and complications, even with their possible advantages. Surgical-related, chemotherapy-related, anesthetic-related, gastrointestinal, organs and systemic complications are the categories into which complications are separated according to frequency, risk factors, and effect on patient outcomes. In this narrative review of the literature, the side effects and complications of HIPEC+CRS in cancer patients with PM are examined. The present knowledge on the incidence, frequency, kinds, and risk factors of acute complications following CRS+HIPEC is summarized in this study. This review emphasizes the need for careful patient selection criteria, precise surgical technique, and thorough intraoperative care to reduce or manage these risks. Moreover, it highlights the need for interdisciplinary collaboration in treating these patients. This study aims to know these complications, improve clinical practice, and guide future studies to increase the safety and efficacy of CRS+HIPEC in treating metastatic colorectal cancer.

    Keywords: Cytoreductive surgery, Hyperthermic intraperitoneal chemotherapy, Peritoneal metastasis, surgical oncology, surgical outcomes, Surgery, operation, Cancer

    Received: 19 Sep 2024; Accepted: 18 Nov 2024.

    Copyright: © 2024 Karimi, Shirsalimi and Sedighi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Mehdi Karimi, Bogomolets National Medical University (NMU), Kyiv, Ukraine

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.